Analyst: The SOL Spot ETF may be approved as early as March 14th, and at the latest by October 10th
On March 3, PANews reported that a macro analyst from Sosovalue stated that under the current SEC regulatory framework, cryptocurrency spot ETFs must undergo dual review of the S-1 registration document and the 19b-4 exchange rule adjustment document. The SEC must announce preliminary results within 45 days after accepting the 19b-4 file and make a final decision within a maximum of 240 days.
Taking Grayscale Solana Trust as an example, its 19b-4 file was accepted by the SEC on February 12. The SEC can refuse or postpone within the first 30 days but cannot directly approve it. Therefore, the earliest approval window is March 14th, with a preliminary review deadline of March 29th. This time point may release key regulatory signals. If Grayscale Solana Trust is approved, SOL spot ETFs such as Bitwise Solana ETF that adopt similar exchange rule adjustment schemes may be approved simultaneously, and market liquidity is expected to initiate pricing response at this stage.
If referring to Bitcoin's spot ETF approval duration (up to 240 days), SOL's latest approval date for its spot ETF would be October10th ,2025 . However in today’s regulatory environment ,the market generally expects that SEC’s approval process might speed up.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Vaxcyte shares soar following successful late-stage clinical trial for pneumococcal vaccine
October 5 – Vaxcyte (PCVX.O) shares surged 26% pre-market to $71.17. Vaxcyte announced that its 31-valent pneumococcal vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, and generated immune responses comparable to or stronger than Pfizer’s Prevnar 20 and Merck’s Capvaxive. The safety and tolerability of the vaccine were similar to existing vaccines. Vaxcyte expects results from two additional late-stage clinical trials in the first half of 2027, and plans to submit a marketing application to the FDA in the first half of 2028. As of the previous trading session’s close, the stock had risen 22.4% year-to-date.
Linde to release Q3 2026 results, hosts investor conference call and webcast
Linde will publish third-quarter 2026 results on Oct. 29, 2026 by 6:00 a.m. EDT (11:00 a.m. CET). Conference call webcast set for Oct. 29, 2026 at 9:00 a.m. EDT (2:00 p.m. CET). Web replay available from Oct. 29, 2026 at 10:30 a.m. EDT (3:30 p.m. CET) via https://www.linde.com/investors/financial-reports. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Linde plc published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2409690_en) on October 05, 2026, and is solely responsible for the information contained therein.
Bitcoin (BTC) Rejected at $87K Again, Cardano (ADA) Soars 11%: Market Watch
BUZZ - PTC shares soar after Schneider Electric agrees to acquire PTC for $22.6 billion
On October 5th, shares of software company PTC (PTC.O) surged by 34.6% in pre-market trading to $193.8 after France's Schneider Electric (SCHN.PA) agreed to acquire PTC in an all-cash deal valuing PTC's equity at approximately $22.6 billion. The offer price of $205 per share represents an enterprise value of $23.7 billion, a 42.3% premium over PTC’s previous closing price. According to data from London Stock Exchange Group (LSEG), this is the largest acquisition in Schneider Electric’s history. Following the agreement to acquire private AI software and industrial data provider Cognite Holding in June this year, this deal marks another significant step in SCHN’s expansion into the software sector. As of the previous day’s close, PTC shares were down 17.3% year-to-date, while SCHN’s shares had risen 17.4% for the year.
Crypto prices
More
